Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: Diagnostic and disease-monitoring implications.
Autoimmune Diseases of the Nervous System
/ diagnostic imaging
Brain
/ diagnostic imaging
Calcinosis
Child, Preschool
Female
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Male
Mutation
Nervous System Malformations
/ diagnostic imaging
Neuroimaging
Ribonuclease H
/ genetics
Tomography, X-Ray Computed
Aicardi-Goutières syndrome
Cerebral calcification
Leukodystrophy
Journal
Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
20
11
2018
revised:
20
02
2019
accepted:
22
02
2019
pubmed:
4
3
2019
medline:
8
11
2019
entrez:
4
3
2019
Statut:
ppublish
Résumé
Aicardi-Goutières syndrome (AGS) is a rare genetic leukoencephalopathy related to inappropriate activation of type I interferon. Neuroradiological findings are typically characterized by white matter abnormalities, cerebral atrophy and cerebral calcification. The disease usually manifests itself during the first year of life in the form of an initial "encephalitic-like" phase followed by a chronic phase of stabilization of the neurological signs. Recently new therapeutic strategies have been proposed aimed at blocking the abnormal activation of the interferon cascade. We reviewed clinical and MRI findings in three young RNASEH2B-mutated patients studied with serial CT and MRI studies. All three patients presented clinical and MRI features consistent with AGS but, very unexpectedly, an improving neuroradiological course. In patient 1, the MRI improvement was noted some months after treatment with high-dose steroid and IVIg treatment; in patients 2 and 3 it occurred spontaneously. Patient 2 did not show cerebral calcification on CT images. Our series highlights the possibility of spontaneous neuroradiological improvement in AGS2 patients, as well as the possibility of absence of cerebral calcification in AGS. The study underlines the need for extreme caution when using MRI as an outcome measure in therapeutic trials specific for this disease. MRI follow-up studies in larger series are necessary to describe the natural course of AGS.
Sections du résumé
BACKGROUND
Aicardi-Goutières syndrome (AGS) is a rare genetic leukoencephalopathy related to inappropriate activation of type I interferon. Neuroradiological findings are typically characterized by white matter abnormalities, cerebral atrophy and cerebral calcification. The disease usually manifests itself during the first year of life in the form of an initial "encephalitic-like" phase followed by a chronic phase of stabilization of the neurological signs. Recently new therapeutic strategies have been proposed aimed at blocking the abnormal activation of the interferon cascade.
MATERIALS AND METHODS
We reviewed clinical and MRI findings in three young RNASEH2B-mutated patients studied with serial CT and MRI studies.
RESULTS
All three patients presented clinical and MRI features consistent with AGS but, very unexpectedly, an improving neuroradiological course. In patient 1, the MRI improvement was noted some months after treatment with high-dose steroid and IVIg treatment; in patients 2 and 3 it occurred spontaneously. Patient 2 did not show cerebral calcification on CT images.
CONCLUSIONS
Our series highlights the possibility of spontaneous neuroradiological improvement in AGS2 patients, as well as the possibility of absence of cerebral calcification in AGS. The study underlines the need for extreme caution when using MRI as an outcome measure in therapeutic trials specific for this disease. MRI follow-up studies in larger series are necessary to describe the natural course of AGS.
Identifiants
pubmed: 30826161
pii: S1096-7192(18)30713-3
doi: 10.1016/j.ymgme.2019.02.006
pii:
doi:
Substances chimiques
ribonuclease HII
EC 3.1.26.-
Ribonuclease H
EC 3.1.26.4
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
489-494Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.